NovaBridge Biosciences (NBP)
1.02
-0.05
(-4.67%)
USD |
NASDAQ |
Nov 03, 13:30
NovaBridge Biosciences Max Drawdown (5Y) : 99.27% for Oct. 31, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| October 31, 2026 | 99.27% |
| September 30, 2026 | 99.27% |
| August 31, 2026 | 99.27% |
| July 31, 2026 | 99.27% |
| June 30, 2026 | 99.27% |
| May 31, 2026 | 99.27% |
| April 30, 2026 | 99.27% |
| March 31, 2026 | 99.27% |
| February 28, 2026 | 99.27% |
| January 31, 2026 | 99.27% |
| December 31, 2025 | 99.27% |
| November 30, 2025 | 99.27% |
| October 31, 2025 | 99.27% |
| September 30, 2025 | 99.27% |
| August 31, 2025 | 99.27% |
| July 31, 2025 | 99.27% |
| June 30, 2025 | 99.27% |
| May 31, 2025 | 99.27% |
| April 30, 2025 | 99.27% |
| March 31, 2025 | 99.05% |
| February 28, 2025 | 98.99% |
| January 31, 2025 | 98.99% |
| December 31, 2024 | 98.99% |
| November 30, 2024 | 98.90% |
| October 31, 2024 | 98.78% |
| Date | Value |
|---|---|
| September 30, 2024 | 98.78% |
| August 31, 2024 | 98.76% |
| July 31, 2024 | 98.60% |
| June 30, 2024 | 98.60% |
| May 31, 2024 | 98.60% |
| April 30, 2024 | 98.60% |
| March 31, 2024 | 98.60% |
| February 29, 2024 | 98.60% |
| January 31, 2024 | 98.60% |
| December 31, 2023 | 98.60% |
| November 30, 2023 | 98.60% |
| October 31, 2023 | 98.60% |
| September 30, 2023 | 98.60% |
| August 31, 2023 | 97.86% |
| July 31, 2023 | 96.84% |
| June 30, 2023 | 96.51% |
| May 31, 2023 | 96.51% |
| April 30, 2023 | 96.49% |
| March 31, 2023 | 96.35% |
| February 28, 2023 | 96.19% |
| January 31, 2023 | 96.19% |
| December 31, 2022 | 96.19% |
| November 30, 2022 | 95.98% |
| October 31, 2022 | 95.98% |
| September 30, 2022 | 95.25% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Xencor, Inc. | 87.01% |
| Arrivent BioPharma, Inc. | -- |
| ACADIA Pharmaceuticals, Inc. | 77.18% |
| Alnylam Pharmaceuticals, Inc. | 66.41% |
| Anika Therapeutics, Inc. | 83.15% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -72.43 |
| Beta (5Y) | 1.705 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 113.7% |
| Historical Sharpe Ratio (5Y) | -0.514 |
| Historical Sortino (5Y) | -1.469 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 35.23% |